This trial is evaluating whether Intraperitoneal Oxaliplatin will improve 5 primary outcomes in patients with Carcinoma. Measurement will happen over the course of 30 days after completion of treatment (estimated to be 22 weeks).
This trial requires 21 total participants across 5 different treatment groups
This trial involves 5 different treatments. Intraperitoneal Oxaliplatin is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"In about 15% of cases, a peritoneal neoplasm is the sole apparent cause of an ascites in a patient with a previous history of malignancy, a negative search for a local recurrence, and without intra-thoracic metastases. Further, about 15% of patients with peritoneal neoplasms develop ascites and then relapse, whereas others develop this symptom, which may be a clue to the diagnosis of neoplasm, even before the detection of an intra-thoracic metastasis." - Anonymous Online Contributor
"The epidemiology of peritoneal neoplasms differs from those of other areas of the body, mainly due to an increased prevalence of appendices, bowel neoplasms and adenocarcinomas." - Anonymous Online Contributor
"There are many treatments used in the treatment of peritoneal neoplasms but the predominant treatment is surgery. There is a need for a systematic review to determine the optimum treatments in the current times of increasing use of other, not yet established, therapies." - Anonymous Online Contributor
"As there are many possible causes to account for abdominal pain, diagnosis of peritoneal neoplasms can be difficult to definitively identify. Although there are some possible signs to look for, it is not possible to definitively rule out all causes of abdominal pain." - Anonymous Online Contributor
"About 4.5 million men with peritoneal neoplasms are diagnosed each year in the United States. Most are diagnosed among whites with early-onset disease. The overall 5-year survival rate is about 80%." - Anonymous Online Contributor
"Results from a recent paper, of the 30 patients who underwent resection, 18 (57%) were able to return to life after surgery but 8 of the 30 (23%) died. For both groups, the 1-year survival rate was 70% (S + E, 100%). For patients treated surgically, it is difficult to determine whether an increased survival time was due to the surgery or from some other cause of death. Results from a recent paper are consistent with a large series of surgeons who had previously reported similar results after curative surgical resection of peritoneal carcinomatosis." - Anonymous Online Contributor
"[Currently, no studies have been done about the use of anti-PD-1/PD-L1 inhibitors and PD-1/PD-L1 pathway inhibitors in this type of cancer.] Ipilimumab showed a potent immunostimulatory function and a low toxicity profile. Anti-PD-1/PD-L1 antibodies showed a strong antitumor activity. Targeted therapies are an option for patients with peritoneal neoplasms, but the identification of molecular pathways to regulate and prevent tumors is needed." - Anonymous Online Contributor
"Peritoneal neoplasms are rare and are more common in older patients. Although most neoplasms are benign, there are also malignant peritoneal neoplasms; moreover, 5 out of 7 cancers are related to other forms of cancer. Peritoneal neoplasms are a challenging group to treat because of the difficulty in obtaining an appropriate resection, the possibility of tumour recurrence and metastasis, and incomplete knowledge of the treatment options. A complete surgical resection is often not possible especially with small, low-grade lesions. Because of the rarity of peritoneal neoplasms and the heterogeneity of the surgical approaches, it is important to develop specific protocols for peritoneal oncological surgery." - Anonymous Online Contributor
"Oxaliplatin-induced side effects are frequent, disabling, and of considerable concern for the patients. The most common toxicity is nephrotoxicity and, accordingly, oxaliplatin should be administered in adequate doses over short periods." - Anonymous Online Contributor
"The following two criteria were identified as most important to include in a clinical trial for peritoneal cancer: 1) a well-defined study population; 2) an indication where surgery or laparotomy plus adjuvant chemotherapy is the sole therapy. We conclude that a clinical trial of peritoneal cancer should be considered when the following is true: 1) the population is well-defined; 2) there is direct proof of an interaction between a surgical intervention and a chemotherapy/adjuvant-chemotherapy; or 3) the population seems to be sufficiently ill that survival benefits are to be expected." - Anonymous Online Contributor
"Oxaliplatin was well-tolerated during this pilot study. Iintraperitoneal chemotherapy with oxaliplatin offers the potential to improve the long-term prognosis of platinum-refractory and platinum-sensitive peritoneal malignancies." - Anonymous Online Contributor
"Many new methods for the treatment of peritoneal cancer have been recently introduced. The use of oxaliplatin has been an option in this respect. However, the use of oxaliplatin in peritoneal cancer is an alternative only under the following circumstances: in combination with the following agents: cisplatin, and if it is necessary to administer more than a 1,000 mg/m3 dose of oxaliplatin. In patients which present a good condition, there are no significant side-effects, so that it can be used alone or combined with cisplatin." - Anonymous Online Contributor